


**Product Name** : BC18630  
**Cat. No.** : PC-49193  
**CAS No.** : 2451935-96-7  
**Molecular Formula** : C<sub>21</sub>H<sub>16</sub>ClN<sub>5</sub>  
**Molecular Weight** : 373.844  
**Target** : E3 Ubiquitin Ligase  
**Solubility** : 10 mM in DMSO



## Biological Activity

BC18630 (BC 18630) is a small molecule inhibitor of the **E3 ubiquitin ligase subunit DCAF7**, potently inhibits SARS-CoV-2 infection with IC<sub>50</sub> of 39 nM in cell-based assays.

BC18630 decreases TFEB ubiquitination and significantly reduces the measured interaction between DCAF7 and TFEB in nucleus of cells.

BC18630 attenuates a wide range of viral infections including SARS-CoV-2 infection, prevents virally-triggered TFEB degradation and dose-dependently reduces OC43 coronavirus infection, reduces HCoV-OC43 NP expression with IC<sub>50</sub> of 0.3 uM.

BC18630 (oral BID at 20mg/kg and 50 mg/kg for 5 days) dose-dependently reduced lung viral titer (PFU) in Syrian hamster model of SARS-CoV-2 infection, significantly reduced SARS-CoV-2 N-protein (NP) in lung, also reduced the observed level of lung injury, with the higher dose particularly reducing inflammatory infiltrates.

## References

Yuan Liu, et al. *Res Sq.* 2021 Apr 23;rs.3.rs-419305.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com